Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 20/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 20/20 | 0.44 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12347222 | 0.92 | ROCK2 (0.45) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL1837484 | 0.77 | ROCK1 (0.54) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL2238343 | 0.76 | ROCK2 (0.46) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL27835155 | 0.73 | ROCK2 (0.60) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL1838095 | 0.68 | ROCK1 (0.64) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL1834620 | 0.68 | ROCK1 (0.59) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL13521500 | 0.67 | CCNT1 (0.44) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL1841846 | 0.65 | ROCK1 (0.66) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL24672666 | 0.65 | ROCK1 (0.61) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL24672657 | 0.65 | ROCK1 (0.61) | ROCK2ROCK1CDC42BPBCDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | ROCK2 1231/4885ROCK1 759/4885CDC42BPB 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.